Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Regeneron Pharmaceuticals (NQ: REGN ) 1,145.03 -5.16 (-0.45%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Regeneron Pharmaceuticals < Previous 1 2 3 4 5 6 7 8 9 ... 34 35 Next > Time To Invest And Or Trade In Bio-Tech Stocks? September 13, 2024 Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... Via Talk Markets Topics ETFs Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry September 11, 2024 Via Benzinga Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease September 11, 2024 Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. Via Benzinga MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits September 11, 2024 MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits Via News Direct Prediction: These 2 Companies Will Split Their Stocks by 2027 September 11, 2024 Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes. Via The Motley Fool $1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today September 10, 2024 Via Benzinga Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock September 09, 2024 Via Benzinga Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry August 27, 2024 Via Benzinga Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030 September 05, 2024 These stocks have generally delivered competitive returns. Via The Motley Fool Biotech And Life Science Sector Update Summer Of 2024 August 29, 2024 It’s the slowest week of the year, we are at the market top and most earnings reports are good. Via Talk Markets 10 Bagger Stocks: Can You Find One? August 23, 2024 Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors. Via Talk Markets What Analysts Are Saying About Regeneron Pharmaceuticals Stock August 23, 2024 Via Benzinga Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment August 20, 2024 Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment. Via Benzinga Exposures Product Safety If You Invested $1000 In This Stock 20 Years Ago, You Would Have $130 Thousand Today August 20, 2024 Via Benzinga Insights Into Regeneron Pharmaceuticals's Performance Versus Peers In Biotechnology Sector August 13, 2024 Via Benzinga $100 Invested In This Stock 20 Years Ago Would Be Worth $15,000 Today August 08, 2024 Via Benzinga Analyst Ratings For Regeneron Pharmaceuticals August 02, 2024 Via Benzinga Biotech Bull Market: 3 Ways To Play It August 20, 2024 Although we are in the later stages of this bull market a cut in interest rates by the Fed should help biotech as you have seen from the recent rally. Via Talk Markets Topics Economy Exposures Interest Rates Alphabet Turns Twenty August 19, 2024 Twenty years ago to the day, the company running the world's largest search engine went public. On August 19th, 2004, Alphabet shares IPO'd at a split-adjusted price of $2.13. Via Talk Markets 7 Stocks That Usually Benefit From a Recession August 13, 2024 These seven stocks have historically shown resilience during economic downturns and could potentially benefit from a recession. Via InvestorPlace 3 Biotech Stocks Poised for a Comeback After Last Week’s Market Meltdown August 13, 2024 Investors should closely watch these three biotech stocks as their strong prospects are likely to help the rebound from market volatility. Via InvestorPlace 3 Biotech Stocks With Promising Drug Pipelines: August 2024 August 08, 2024 The biotech stocks with promising pipelines could see shares soar if drugs in late-stage trials get FDA approval. Via InvestorPlace Exposures Product Safety Exploring The Competitive Space: Regeneron Pharmaceuticals Versus Industry Peers In Biotechnology July 30, 2024 Via Benzinga 3 Healthcare Stocks Positioned for Possible Market Outperformance August 07, 2024 While healthcare stocks might not be as shiny as they were in the pandemic era, these three could outperform the broader market. Via InvestorPlace Is Regeneron Pharmaceuticals Due for a Stock Split? August 03, 2024 Would a stock split help lead Regeneron Pharmaceuticals shares higher? Via The Motley Fool Stock Market Takes Bearish Turn; Apple, Microsoft, Meta, Amazon, AMD In Focus: Weekly Review August 02, 2024 Apple and Meta had strong results, while AI spending remains robust. Via Investor's Business Daily Topics Artificial Intelligence Exposures Artificial Intelligence Regeneron Pharmaceuticals' Q2 Earnings Exceed Estimates, Driven By Its Top-Selling Eczema And Eye Drugs August 01, 2024 Regeneron Pharmaceuticals Q2 results: adjusted EPS of $11.56 (up 13%), revenue of $3.55 billion (up 12%). Key drivers: Eylea HD, Dupixent, and Libtayo. Notable: 18% decline in Eylea US sales; 42%... Via Benzinga US Stocks Tumble On Economic, Geopolitical Concerns; Small Caps, Chipmakers Sink; Meta Rallies: What's Driving Markets Thursday? August 01, 2024 Markets experienced a sharp downturn, driven by heightened geopolitical tensions and economic uncertainties that negatively impacted investor risk sentiment, just a day after the Federal Open Market... Via Benzinga Regeneron Stock Climbs After Strong Second-Quarter Performance August 01, 2024 A strong second-quarter performance lifted the already extended shares of the New York-based drug maker Regeneron. Via Investor's Business Daily Wall Street Looks To Ride On Earnings Cheer As Meta Q2 Impresses Investors: Analyst Says Economic Data, Stock Performances Suggest Republican Win In November August 01, 2024 After Wednesday’s tech-led rebound amid the Federal Reserve’s rate decision, the stock market could be in for further gains. The major index futures point to a higher opening, although suggesting a... Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 34 35 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.